Fed Sparks Profit T...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$12.47 0.11 | 0.89%
05/24/13 - 04:04 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 12.47 |
| 52 Week High | 14.60 |
| 52 Week Low | 9.37 |
| Avg. Daily Vol. (Mil) | 6.96 |
| Beta (3 year) | 1.25 |
| Share Related Items | |
| Mkt Cap (Mil) | 7,459.46 |
| Shares Out (Mil) | 598.19 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 0.90 |
| Current Ratio | 1.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.88 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | -25.90 |
| Price/Book | 10.93 |
| Price/Cash Flow | -560.00 |
| Per Share Data | |
| Earnings | -0.06 |
| Sales | -0.48 |
| Book Value | 1.14 |
| Cash Flow | -0.02 |
| Business Summary | |
|---|---|
| Elan Corporation, PLC is a neuroscience-based biotechnology company, which operates its business in two areas BioNeurology and EDT. | |
| General Information | |
| Treasury Building
Lower Grand Canal Street Dublin, 2 |
|
| www.elan.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 245 | |
| CEO: G. Kelly Martin | |
| Short Interest | |
| Current Month (Mil) | 10.89 |
| Previous Month (Mil) | 12.68 |
| Short Interest Ratio (Days) | 1.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -2.60 |
| Return on Investments | -6.20 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 14.70 |
Portfolios with ELN
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- ContributorMost-Active Stocks for the ...
- ProTPG-Axon Capital
- Contributor22 Biopharma Stocks With Br...
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
- ProRobert Bruce
Latest ELN Headlines from TheStreet
- Dollar Strength Hits Oil, Gold
05.13.13 | 08:05 am - Stock Futures Lower Ahead of Retail Sales 05.13.13 | 06:05 am
- Why This Fund Manager Is Short Ziopharm 03.22.13 | 07:03 am
- SAC to Pay Record Insider Trading Penalty 03.16.13 | 11:03 am
- Dow Sets Another Record as Stocks Rise 03.11.13 | 04:03 pm
- You Have to Love a Lucrative 'Drug Deal' 02.28.13 | 06:02 am
- Royalty Pharma: Don't Let Elan Piss Away $3 Billion On Stupid Acquisitions 02.25.13 | 09:02 am
- 2 Hot Stocks to Trade (or Not) 02.07.13 | 02:02 pm
- Before the Bell: Feb. 6 02.06.13 | 08:02 am
- The Digital Skeptic: Insider Trading? Why Even Bother? 12.04.12 | 08:12 am
Press Releases for ELN
- Royalty Pharma Announces Firm Offer To Acquire Elan - PR Newswire 04.15.13 | 07:04 am
- New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status - Business Wire 03.18.13 | 07:03 am
- Elan Discloses Filing Of Share Repurchase Tender Offer Documentation - Business Wire 03.12.13 | 01:03 pm
- Elan Provides Update On Tysabri Transaction And $1bn Share Repurchase - Business Wire 03.08.13 | 04:03 pm
- Elan’s Response To Royalty Pharma Statement Of Today - Business Wire 03.06.13 | 09:03 am
- Elan Announces Further Unlocking Of Value To Benefit Shareholders - Business Wire 03.04.13 | 01:03 am
- Elan Announces The Appointment Of Mr. John Given As General Counsel - Business Wire 02.28.13 | 02:02 am
- Elan’s Response To Indication Of Interest - Business Wire 02.25.13 | 09:02 am
- Elan Provides Update Post Restructuring Announcement Of Tysabri Collaboration - Business Wire 02.22.13 | 02:02 am
- Elan Announces Filing Of Annual Report On Form 20-F For Year Ended December 31, 2012 - Business Wire 02.12.13 | 04:02 pm
Partner Headlines for ELN
- Alkermes Earnings Beat Estimates, But Outlook Unclear - Investor's Business Daily 05.23.13 | 06:05 pm
- Elan Issues Response to Royalty Pharma Bid, Tells Holders to Take No Action - Benzinga 05.20.13 | 01:05 pm
- Theravance, Glaxo, Elan Star In Biotech Soap Opera - Investor's Business Daily 05.13.13 | 05:05 pm
- Alzheimer's keeps frustrating big pharma - MSN Money 05.13.13 | 10:05 am
- Acorda: A Biotech Company To Consider - Seeking Alpha 04.13.13 | 09:04 am
- Benzinga's Top Pre-Market Gainers - Benzinga 04.12.13 | 09:04 am
- After Hours Most Active for Feb 6, 2013 : T, BMY, FCX, KMI, NOK, HCBK, QQQ, ELN, GMCR, VMED, NWSA, WCRX - NASDAQ 02.06.13 | 09:02 pm
- Stocks Lower In Choppy Trade; Aruba, Trimble Slide - Investor's Business Daily 02.06.13 | 03:02 pm
- Pre-Market Most Active for Feb 6, 2013 : ELN, QQQ, BAC, BBRY, ZNGA, NOK, GSK, VMED, KB, SNY, ARMH, CLDX - NASDAQ 02.06.13 | 01:02 pm
- Biogen Stock Hits New High On Tysabri Buyout - Investor's Business Daily 02.06.13 | 10:02 am
